Johnson & Johnson (JNJ) Non-Current Assets (2009 - 2026)
Johnson & Johnson (JNJ) posted Non-Current Assets of $141.3 billion for Q2 2026, little changed sequentially from $141.7 billion in Q1 2026, and up 1.73% YoY from $138.9 billion in Q2 2025.
Johnson & Johnson (JNJ) Non-Current Assets (2009 - 2026) Analysis & Trends
Johnson & Johnson has reported Non-Current Assets for 18 years, with the latest figure at $141.3 billion in Q2 2026.
- Quarterly Non-Current Assets rose 1.73% year-over-year to $141.3 billion in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $564.8 billion (up 10.69% YoY) and the FY2025 annual result came in at $143.6 billion, up 15.6% from the prior year.
- Non-Current Assets held at $141.3 billion in Q2 2026 per JNJ's latest filing, from $141.7 billion in the prior quarter.
- Over five years, Non-Current Assets peaked at $143.6 billion in Q4 2025 and troughed at $109.9 billion in Q4 2022.
- A 5-year average of $126.2 billion and a median of $124.2 billion in 2024 frame the typical range for Non-Current Assets.
- The sharpest annual moves came in 2023 and 2026: Non-Current Assets fell 13.64% in 2023, then rose 16.05% in 2026.
- Over 5 years, Non-Current Assets stood at $109.9 billion in 2022, then gained by 3.8% to $114.1 billion in 2023, then rose by 8.9% to $124.2 billion in 2024, then grew by 15.6% to $143.6 billion in 2025, then decreased by 1.6% to $141.3 billion in 2026.
- According to Business Quant data, Non-Current Assets over the past three periods registered $141.3 billion, $141.7 billion, and $143.6 billion for Q2 2026, Q1 2026, and Q4 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 652.29 Bn | 631.53 Bn | 17.26 Bn | 141.29 Bn |
| 2 | AbbVie | 470.62 Bn | 464.06 Bn | 12.70 Bn | 101.45 Bn |
| 3 | Merck | 375.66 Bn | 368.52 Bn | 12.21 Bn | 125.00 Mn |
| 4 | Novartis Ag | 302.90 Bn | 295.21 Bn | 11.24 Bn | 94.68 Bn |
| 5 | Astrazeneca | 257.50 Bn | 252.60 Bn | 12.86 Bn | 87.87 Bn |
| 6 | Amgen | 237.19 Bn | 223.20 Bn | 7.24 Bn | 60.68 Bn |
| 7 | Gilead Sciences | 182.92 Bn | 179.74 Bn | 6.22 Bn | 35.42 Bn |
| 8 | Pfizer | 160.14 Bn | 148.44 Bn | 10.94 Bn | 159.77 Bn |
| 9 | Gsk | 106.08 Bn | 101.91 Bn | 8.24 Bn | 59.27 Bn |
| 10 | Sanofi | 55.22 Bn | 47.84 Bn | 10.79 Bn | 113.37 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 28, 2026 | 141.29 Bn |
| Mar 29, 2026 | 141.72 Bn |
| Dec 28, 2025 | 143.59 Bn |
| Sep 28, 2025 | 138.21 Bn |
| Jun 29, 2025 | 138.89 Bn |
| Mar 30, 2025 | 122.12 Bn |
| Dec 29, 2024 | 124.21 Bn |
| Sep 29, 2024 | 125.04 Bn |
| Jun 30, 2024 | 123.27 Bn |
| Mar 31, 2024 | 114.96 Bn |
| Dec 31, 2023 | 114.06 Bn |
| Oct 1, 2023 | 112.36 Bn |
| Jul 2, 2023 | 131.12 Bn |
| Apr 2, 2023 | 131.58 Bn |
| Jan 1, 2023 | 132.08 Bn |
| Oct 2, 2022 | 109.89 Bn |
| Jul 3, 2022 | 113.88 Bn |
| Apr 3, 2022 | 117.93 Bn |
| Jan 2, 2022 | 121.04 Bn |
| Oct 3, 2021 | 119.34 Bn |